Jump to Header Jump to Main Content Jump to Footer

Ph II Subcutan Amivantamab in Pts w/ Adv or Metastat SolidTumors EGFR-mutated Non-Small Cell Lung Ca

Misako Nagasaka

A Study On:

  • Anus
  • Bones and Joints
  • Brain and Nervous System
  • Breast
  • Cervix
  • Colon
  • Corpus Uteri
  • Esophagus
  • Eye and Orbit
  • Ill-Defined Sites
  • Kaposi's Sarcoma
  • Kidney
  • Larynx
  • Lip, Oral Cavity and Pharynx
  • Liver
  • Lung
  • Melanoma, Skin
  • Mycosis Fungoides
  • Other Digestive Organ
  • Other Endocrine System
  • Other Female Genital
  • Other Male Genital
  • Other Respiratory and Intrathoracic Organs
  • Other Skin
  • Other Urinary
  • Ovary
  • Pancreas
  • Prostate
  • Rectum
  • Small Intestine
  • Soft Tissue
  • Stomach
  • Thyroid
  • Unknown Sites
  • Urinary Bladder


  • Open


18 Years and older (Adult, Older Adult )

Official Title

A Phase II, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer


The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).


You can join if...


-Participant must have histologically or cytologically confirmed, locally advanced or metastatic, non-small cell lung cancer (NSCLC)

  • articipants must have at least 1 measurable lesion, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
    -May have a prior or concurrent second malignancy
    -Have adequate organ
    -A participant must agree not to donate eggs (ova, oocytes) or freeze for future use
    -Participant has a medical history of interstitial lung disease (ILD), including drug induced ILD or radiation pneumonitis
    -Participant has a history of hypersensitivity to any excipients of the investigational products to be used in their enrollment cohort
    -Participant has received a live or live attenuated vaccine within 3 months before Cycle 1 Day 1.
    -Participant is currently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5)
    -Other clinically active liver disease of infectious origin
    -Participant has a history of clinically significant cardiovascular disease
    -Participant has symptomatic brain metastases

Get in touch with our study team